Home › Research › Treatments
Amyloid imaging in Alzheimer's disease
Nordberg A.. Neuropsychologia, 2008-04-08
Topic: Amyloid, tau and blood-test diagnosis
Alzheimer's disease (AD) is a complex neurodegenerative disorder of which the exact cause is still not known. There has, however, been remarkable progress in the understanding of the pathophysiological events that underlie the disease with a focus on amyloid formation. We do not know yet if amyloid is the most crucial target for an effective therapy in AD. The new amyloid PET imaging tracer ligands offer possibilities for measuring fibrillar beta amyloid (Abeta) in the brain and for studying the time course of amyloid in the brain. This opens up new possibilities for early diagnosis as well as new tools for monitoring anti-amyloid therapy in AD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Nordberg, A. (2008). Amyloid imaging in Alzheimer's disease. Neuropsychologia. https://doi.org/10.1016/j.neuropsychologia.2008.03.020
Vancouver
Nordberg A. Amyloid imaging in Alzheimer's disease. Neuropsychologia. 2008. doi:10.1016/j.neuropsychologia.2008.03.020. PMID: 18468648.
BibTeX
@article{nordberg2008-18468648,
author = {Nordberg, A.},
title = {{Amyloid imaging in Alzheimer's disease}},
journal = {Neuropsychologia},
year = {2008},
doi = {10.1016/j.neuropsychologia.2008.03.020},
pmid = {18468648},
url = {https://doi.org/10.1016/j.neuropsychologia.2008.03.020}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Alzheimer's disease (AD) is a complex neurodegenerative disorder of which the exact cause is still not known.
- There has, however, been remarkable progress in the understanding of the pathophysiological events that underlie the disease with a focus on amyloid formation.
- We do not know yet if amyloid is the most crucial target for an effective therapy in AD.
- The new amyloid PET imaging tracer ligands offer possibilities for measuring fibrillar beta amyloid (Abeta) in the brain and for studying the time course of amyloid in the brain.
- This opens up new possibilities for early diagnosis as well as new tools for monitoring anti-amyloid therapy in AD.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 36/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 21 of the 58 points we could judge it on, which is 36 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neuropsychologia) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2008 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 18468648) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 21 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 21 of the 58 points we could judge it on is 36 out of 100. |
| Total | 36 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments
Also in Treatments
197 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.